Lupin has obtained approval from the USFDA to market a generic form of an HIV medication. The approved drug, equivalent to Symtuza tablets, positions Lupin as the exclusive first-to-file. The tablets ...

The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily ...

Lupin receives US FDA tentative approval for generic Symtuza tablets: Our Bureau, Mumbai Monday, February 3, 2025, 13:45 Hrs [IST] Global pharma major Lupin Limited (Lupin) announ ...

Mumbai: Global pharma major Lupin Limited has announced that the United States Food and Drug Administration (U.S. FDA) has ...

Mumbai: In a fresh challenge to Novartis' blockbuster heart failure drug Entresto, Indian generics maker Lupin has received ...

This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who ...

US FDA completes pre-approval inspection of Lupin’s edaravone oral suspension facility in Somerset with no observations: Our Bureau, Mumbai Monday, February 3, 2025, 14:45 Hrs [ ...

Earlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 ...

Lupin has announced that the the United States Food and Drug Administration (US FDA) has concluded the pre-approval inspection of the company's Edaravone Oral Suspension, located at its manufacturing ...

A meeting of the board of directors of the company is scheduled to be held on February 11, 2025, to consider and approve the ...

Lupin has received tentative approval from the USFDA to market a generic HIV drug in the US under PEPFAR. The drug, made at ...

The company's product is a generic equivalent of ViiV Healthcare Company's ... thereby significantly boosting our HIV medication portfolio," Lupin Executive Director, Global CFO & Head of API Plus SBU ...